Valuation: Sprint Bioscience AB

Market Cap 41Cr 4.23Cr 3.7Cr 3.41Cr 3.15Cr 5.97Cr 402.96Cr 6.07Cr 16Cr 198.51Cr 16Cr 16Cr 682.44Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 41Cr 4.23Cr 3.7Cr 3.41Cr 3.15Cr 5.97Cr 402.96Cr 6.07Cr 16Cr 198.51Cr 16Cr 16Cr 682.44Cr EV / Sales 2026 *
4.8x
EV / Sales 2027 * 2.63x
Free-Float
64.78%
Yield 2026 *
-
Yield 2027 * -
1 day+1.58%
1 week-5.16%
Current month-6.76%
1 month+4.89%
3 months+5.46%
6 months+147.44%
Current year+162.59%
1 week 3.55
Extreme 3.55
3.99
1 month 3.55
Extreme 3.55
4.59
Current year 1.36
Extreme 1.355
4.59
1 year 0.48
Extreme 0.477
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
9.36
10 years 0.36
Extreme 0.36
41.9
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.58%-5.16%+672.00%+620.15% 4.23Cr
+1.84%-0.66%+59.82%+94.48% 5.49TCr
-4.14%-8.06%+58.96%+125.71% 5.46TCr
-2.24%+3.59%+17.75%+469.23% 2.51TCr
-1.60%-6.21%-18.96%-16.06% 2.31TCr
-0.42%-0.26%+40.93%-7.37% 1.99TCr
-3.19%0.00%+35.60%-27.49% 1.75TCr
-6.84%+2.18%+195.12%+364.56% 1.65TCr
-4.55%-5.83%+43.82%+619.71% 1.57TCr
-1.05%+1.16%+25.95%+191.69% 1.42TCr
Average -2.09%-0.77%+113.10%+243.46% 2.42TCr
Weighted average by Cap. -2.02%-1.45%+50.72%+171.07%

Financials

2026 *2027 *
Net sales 8.48Cr 87.97L 76.95L 70.97L 65.55L 1.24Cr 84Cr 1.26Cr 3.33Cr 41Cr 3.3Cr 3.23Cr 142.09Cr 16Cr 1.61Cr 1.41Cr 1.3Cr 1.2Cr 2.27Cr 153.35Cr 2.31Cr 6.09Cr 76Cr 6.04Cr 5.91Cr 259.71Cr
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
10/26/10 SEK 3.860 +1.58% 1,75,472
09/26/09 SEK 3.800 0.00% 2,72,825
08/26/08 SEK 3.800 -2.06% 1,48,749
07/26/07 SEK 3.880 +4.86% 3,19,257
06/26/06 SEK 3.700 -9.09% 5,38,988

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock